Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer | Nature Communications
No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis - The
Ribociclib Improves Survival in Advanced Breast Cancer - National Cancer Institute
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients - ESMO Open
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast
ASCO 2021: Addition of Palbociclib to Fulvestrant Attains Overall Survival Benefit in Advanced Breast Cancer With Update of PALOMA-3 | PracticeUpdate
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials | SpringerLink
PALOMA-3 Exploratory Analysis Who Benefits Most From Palbociclib - The ASCO Post
Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3 - Rugo - 2021 - The Oncologist - Wiley Online Library
Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer - touchONCOLOGY
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer | NEJM
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Efficacy of Palbociclib Combinations in Hormone Receptor–Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment - Clinical Breast Cancer
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer - European Journal of Cancer
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
